- Biotechnology
- Healthcare
Vertex Pharmaceuticals Incorporated
VRTX · US ·
NASDAQ
468.45
USD
+2.49
(0.53%)
-
-1.90
EPS
-
-246.80
P/E
-
121B
MARKET CAP
-
0.00%
DIV YIELD
Executives
Name | Title | Pay |
---|---|---|
Susie Lisa | Senior Vice President of Investor Relations | -- |
Mr. Charles F. Wagner Jr. | Executive Vice President & Chief Financial Officer | 2.12M |
Dr. David M. Altshuler M.D., Ph.D. | Executive Vice President & Chief Scientific Officer | 2.17M |
Dr. Reshma Kewalramani FASN, M.D. | Chief Executive Officer, President & Director | 5.59M |
Ms. Nina Devlin | Senior Vice President & Chief Communications Officer | -- |
Ms. Kristen C. Ambrose CPA | Senior Vice President & Chief Accounting Officer | -- |
Mr. Jonathan Biller J.D. | Executive Vice President & Chief Legal Officer | -- |
Mr. Mike Tirozzi | SVice President and Chief Information & Data Officer | -- |
Mr. Stuart A. Arbuckle B.Sc. | Executive Vice President & Chief Operating Officer | 2.76M |
Dr. Jeffrey Marc Leiden M.D., Ph.D. | Executive Chairman | 95K |
Insider Transactions
Date | Name | Title | Acquisition Or Disposition | Stock / Options | # of Shares | Price |
---|---|---|---|---|---|---|
2024-08-07 | Bozic Carmen | EVP and CMO | D - S-Sale | Common Stock | 2280 | 476.75 |
2024-08-01 | SACHS BRUCE I | director | A - M-Exempt | Common Stock | 5295 | 125.71 |
2024-08-01 | SACHS BRUCE I | director | D - S-Sale | Common Stock | 5295 | 508 |
2024-08-01 | SACHS BRUCE I | director | D - M-Exempt | Stock Option (Right to Buy) | 5295 | 125.71 |
2024-07-30 | Kewalramani Reshma | CEO & President | D - S-Sale | Common Stock | 15202 | 505 |
2024-07-24 | Bozic Carmen | EVP and CMO | D - S-Sale | Common Stock | 2280 | 488.46 |
2024-07-22 | Kewalramani Reshma | CEO & President | D - S-Sale | Common Stock | 15202 | 497 |
2024-07-15 | SACHS BRUCE I | director | A - A-Award | Deferred Stock Units | 89.264 | 0 |
2024-07-10 | Bozic Carmen | EVP and CMO | D - S-Sale | Common Stock | 2280 | 487.34 |
2024-06-26 | Bozic Carmen | EVP and CMO | D - S-Sale | Common Stock | 2280 | 471.72 |
2024-06-12 | Bozic Carmen | EVP and CMO | D - S-Sale | Common Stock | 2280 | 478 |
2024-06-11 | Atkinson Edward Morrow III | EVP, Chief Technical Ops. Off. | D - F-InKind | Common Stock | 6824 | 481.96 |
2024-06-12 | Atkinson Edward Morrow III | EVP, Chief Technical Ops. Off. | D - S-Sale | Common Stock | 7288 | 478 |
2024-06-05 | Sachdev Amit | EVP Chief Patient & Ext Af Off | D - G-Gift | Common Stock | 4600 | 0 |
2024-06-03 | WAGNER CHARLES F JR | EVP & Chief Financial Officer | D - S-Sale | Common Stock | 3250 | 460 |
2024-06-03 | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | D - S-Sale | Common Stock | 2175 | 460 |
2024-05-30 | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | D - S-Sale | Common Stock | 2350 | 439.11 |
2024-05-31 | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | D - S-Sale | Common Stock | 2250 | 445 |
2024-05-29 | Bozic Carmen | EVP and CMO | D - S-Sale | Common Stock | 2280 | 445.56 |
2024-05-28 | WAGNER CHARLES F JR | EVP & Chief Financial Officer | D - S-Sale | Common Stock | 3250 | 454.79 |
2024-05-24 | Kewalramani Reshma | CEO & President | A - M-Exempt | Common Stock | 1565 | 187.53 |
2024-05-24 | Kewalramani Reshma | CEO & President | D - S-Sale | Common Stock | 1565 | 457 |
2024-05-24 | Kewalramani Reshma | CEO & President | D - M-Exempt | Stock Option (Right to Buy) | 1565 | 187.53 |
2024-05-22 | SACHS BRUCE I | director | A - M-Exempt | Common Stock | 7073 | 93.51 |
2024-05-22 | SACHS BRUCE I | director | D - S-Sale | Common Stock | 7073 | 448 |
2024-05-22 | SACHS BRUCE I | director | D - M-Exempt | Stock Option (Right to Buy) | 7073 | 93.51 |
2024-05-20 | Kewalramani Reshma | CEO & President | D - S-Sale | Common Stock | 15202 | 447 |
2024-05-15 | Sachdev Amit | EVP Chief Patient & Ext Af Off | D - S-Sale | Common Stock | 32 | 430.93 |
2024-05-15 | Arbuckle Stuart A | EVP, COO | D - S-Sale | Common Stock | 69 | 430.93 |
2024-05-15 | ALTSHULER DAVID | EVP, Chief Scientific Officer | D - S-Sale | Common Stock | 54 | 430.93 |
2024-05-15 | Schneider Jennifer | director | A - A-Award | Common Stock | 922 | 0 |
2024-05-15 | Schneider Jennifer | - | 0 | 0 | ||
2024-05-14 | Atkinson Edward Morrow III | EVP, Chief Technical Ops. Off. | A - A-Award | Common Stock | 14112 | 0 |
2024-05-01 | Upadhyay Suketu | director | A - A-Award | Common Stock | 1001 | 0 |
2024-05-01 | Upadhyay Suketu | director | D - D-Return | Common Stock | 1168 | 0 |
2024-05-01 | Upadhyay Suketu | director | A - A-Award | Deferred Stock Units | 1168 | 0 |
2024-05-01 | Thornberry Nancy | director | A - A-Award | Common Stock | 501 | 0 |
2024-05-01 | Thornberry Nancy | director | A - A-Award | Stock Option (Right to Buy) | 1571 | 399.71 |
2024-05-01 | SACHS BRUCE I | director | A - A-Award | Stock Option (Right to Buy) | 3142 | 399.71 |
2024-05-01 | MCKENZIE DIANA | director | A - A-Award | Deferred Stock Units | 1168 | 0 |
2024-05-01 | MCKENZIE DIANA | director | A - A-Award | Common Stock | 1001 | 0 |
2024-05-01 | MCKENZIE DIANA | director | D - D-Return | Common Stock | 1168 | 0 |
2024-05-01 | Lagarde Michel | director | A - A-Award | Stock Option (Right to Buy) | 3142 | 399.71 |
2024-05-01 | Kearney Terrence C | director | A - A-Award | Stock Option (Right to Buy) | 3142 | 399.71 |
2024-05-01 | Garber Alan M | director | A - A-Award | Stock Option (Right to Buy) | 3142 | 399.71 |
2024-05-01 | CARNEY LLOYD | director | A - A-Award | Common Stock | 1001 | 0 |
2024-05-01 | Bhatia Sangeeta N. | director | A - A-Award | Common Stock | 1001 | 0 |
2024-05-02 | Bhatia Sangeeta N. | director | D - S-Sale | Common Stock | 467 | 402.95 |
2024-04-15 | SACHS BRUCE I | director | A - A-Award | Deferred Stock Units | 109.49 | 0 |
2024-04-01 | Ambrose Kristen | SVP & Chief Accounting Officer | D - F-InKind | Common Stock | 225 | 418.1 |
2024-04-02 | Ambrose Kristen | SVP & Chief Accounting Officer | D - S-Sale | Common Stock | 240 | 419 |
2024-02-23 | WAGNER CHARLES F JR | EVP & Chief Financial Officer | D - F-InKind | Common Stock | 3309 | 431.79 |
2024-02-23 | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | D - F-InKind | Common Stock | 3309 | 431.79 |
2024-02-26 | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | D - S-Sale | Common Stock | 354 | 425.7 |
2024-02-23 | Sachdev Amit | EVP Chief Patient & Ext Af Off | D - F-InKind | Common Stock | 2469 | 431.79 |
2024-02-26 | Sachdev Amit | EVP Chief Patient & Ext Af Off | D - S-Sale | Common Stock | 3004 | 425.7 |
2024-02-23 | Kewalramani Reshma | CEO & President | D - F-InKind | Common Stock | 9386 | 431.79 |
2024-02-23 | Bozic Carmen | EVP and CMO | D - F-InKind | Common Stock | 3309 | 431.79 |
2024-02-23 | Atkinson Edward Morrow III | EVP, Chief Technical Ops. Off. | D - F-InKind | Common Stock | 1654 | 431.79 |
2024-02-26 | Atkinson Edward Morrow III | EVP, Chief Technical Ops. Off. | D - S-Sale | Common Stock | 883 | 425.7 |
2024-02-23 | Arbuckle Stuart A | EVP, COO | D - F-InKind | Common Stock | 4714 | 431.79 |
2024-02-26 | Arbuckle Stuart A | EVP, COO | D - S-Sale | Common Stock | 5034 | 425.7 |
2024-02-23 | Ambrose Kristen | SVP & Chief Accounting Officer | D - F-InKind | Common Stock | 828 | 431.79 |
2024-02-26 | Ambrose Kristen | SVP & Chief Accounting Officer | D - S-Sale | Common Stock | 883 | 425.7 |
2024-02-23 | ALTSHULER DAVID | EVP, Global Research and CSO | D - F-InKind | Common Stock | 3970 | 431.79 |
2024-02-26 | ALTSHULER DAVID | EVP, Global Research and CSO | D - S-Sale | Common Stock | 4239 | 425.7 |
2024-02-21 | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | D - S-Sale | Common Stock | 360 | 421.77 |
2024-02-21 | Sachdev Amit | EVP Chief Patient & Ext Af Off | D - S-Sale | Common Stock | 3191 | 421.77 |
2024-02-21 | Atkinson Edward Morrow III | EVP, Chief Technical Ops. Off. | D - S-Sale | Common Stock | 1201 | 421.77 |
2024-02-21 | Arbuckle Stuart A | EVP, COO | D - S-Sale | Common Stock | 3603 | 421.77 |
2024-02-21 | ALTSHULER DAVID | EVP, Global Research and CSO | D - S-Sale | Common Stock | 3002 | 421.77 |
2024-02-16 | WAGNER CHARLES F JR | EVP & Chief Financial Officer | D - F-InKind | Common Stock | 3750 | 424.01 |
2024-02-20 | WAGNER CHARLES F JR | EVP & Chief Financial Officer | D - F-InKind | Common Stock | 2812 | 420.58 |
2024-02-16 | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | D - F-InKind | Common Stock | 4499 | 424.01 |
2024-02-20 | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | D - F-InKind | Common Stock | 3373 | 420.58 |
2024-02-20 | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | D - S-Sale | Common Stock | 480 | 420.79 |
2024-02-16 | Sachdev Amit | EVP Chief Patient & Ext Af Off | D - F-InKind | Common Stock | 3498 | 424.01 |
2024-02-20 | Sachdev Amit | EVP Chief Patient & Ext Af Off | D - F-InKind | Common Stock | 2623 | 420.58 |
2024-02-20 | Sachdev Amit | EVP Chief Patient & Ext Af Off | D - S-Sale | Common Stock | 4254 | 420.79 |
2024-02-20 | LEIDEN JEFFREY M | Executive Chairman | D - F-InKind | Common Stock | 4118 | 420.58 |
2024-02-16 | Kewalramani Reshma | CEO & President | D - F-InKind | Common Stock | 9359 | 424.01 |
2024-02-20 | Kewalramani Reshma | CEO & President | D - F-InKind | Common Stock | 7019 | 420.58 |
2024-02-16 | Bozic Carmen | EVP and CMO | D - F-InKind | Common Stock | 3750 | 424.01 |
2024-02-20 | Bozic Carmen | EVP and CMO | D - F-InKind | Common Stock | 2812 | 420.58 |
2024-02-16 | Atkinson Edward Morrow III | EVP, Chief Technical Ops. Off. | D - F-InKind | Common Stock | 1501 | 424.01 |
2024-02-20 | Atkinson Edward Morrow III | EVP, Chief Technical Ops. Off. | D - F-InKind | Common Stock | 1125 | 420.58 |
2024-02-20 | Atkinson Edward Morrow III | EVP, Chief Technical Ops. Off. | D - S-Sale | Common Stock | 801 | 420.79 |
2024-02-16 | Arbuckle Stuart A | EVP, COO | D - F-InKind | Common Stock | 4499 | 424.01 |
2024-02-20 | Arbuckle Stuart A | EVP, COO | D - F-InKind | Common Stock | 3373 | 420.58 |
2024-02-20 | Arbuckle Stuart A | EVP, COO | D - S-Sale | Common Stock | 4804 | 420.79 |
2024-02-16 | ALTSHULER DAVID | EVP, Global Research and CSO | D - F-InKind | Common Stock | 3750 | 424.01 |
2024-02-20 | ALTSHULER DAVID | EVP, Global Research and CSO | D - F-InKind | Common Stock | 2812 | 420.58 |
2024-02-20 | ALTSHULER DAVID | EVP, Global Research and CSO | D - S-Sale | Common Stock | 4002 | 420.79 |
2024-02-14 | LEIDEN JEFFREY M | Executive Chairman | D - S-Sale | Common Stock | 4356 | 419.04 |
2024-02-15 | LEIDEN JEFFREY M | Executive Chairman | D - S-Sale | Common Stock | 4655 | 419.16 |
2024-02-12 | LEIDEN JEFFREY M | Executive Chairman | D - S-Sale | Common Stock | 2009 | 419.22 |
2024-02-12 | LEIDEN JEFFREY M | Executive Chairman | D - S-Sale | Common Stock | 647 | 420.39 |
2024-02-13 | LEIDEN JEFFREY M | Executive Chairman | D - S-Sale | Common Stock | 737 | 419.13 |
2024-02-09 | WAGNER CHARLES F JR | EVP & Chief Financial Officer | D - F-InKind | Common Stock | 2607 | 422.74 |
2024-02-09 | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | D - F-InKind | Common Stock | 2100 | 422.74 |
2024-02-12 | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | D - S-Sale | Common Stock | 314 | 420.24 |
2024-02-09 | Sachdev Amit | EVP Chief Patient & Ext Af Off | D - F-InKind | Common Stock | 2022 | 422.74 |
2024-02-12 | Sachdev Amit | EVP Chief Patient & Ext Af Off | D - S-Sale | Common Stock | 3222 | 420.24 |
2024-02-09 | Kewalramani Reshma | CEO & President | D - F-InKind | Common Stock | 8255 | 422.74 |
2024-02-09 | Bozic Carmen | EVP and CMO | D - F-InKind | Common Stock | 2100 | 422.74 |
2024-02-09 | Biller Jonathan | EVP and Chief Legal Officer | D - F-InKind | Common Stock | 1588 | 422.74 |
2024-02-12 | Biller Jonathan | EVP and Chief Legal Officer | D - S-Sale | Common Stock | 1738 | 418.77 |
2024-02-09 | Atkinson Edward Morrow III | EVP, Chief Technical Ops. Off. | D - F-InKind | Common Stock | 832 | 422.74 |
2024-02-12 | Atkinson Edward Morrow III | EVP, Chief Technical Ops. Off. | D - S-Sale | Common Stock | 913 | 420.24 |
2024-02-09 | Arbuckle Stuart A | EVP, COO | D - F-InKind | Common Stock | 3177 | 422.74 |
2024-02-12 | Arbuckle Stuart A | EVP, COO | D - S-Sale | Common Stock | 4295 | 420.24 |
2024-02-09 | Ambrose Kristen | SVP & Chief Accounting Officer | D - F-InKind | Common Stock | 591 | 422.74 |
2024-02-12 | Ambrose Kristen | SVP & Chief Accounting Officer | D - S-Sale | Common Stock | 1374 | 420.24 |
2024-02-09 | ALTSHULER DAVID | EVP, Global Research and CSO | D - F-InKind | Common Stock | 2099 | 422.74 |
2024-02-12 | ALTSHULER DAVID | EVP, Global Research and CSO | D - S-Sale | Common Stock | 3145 | 420.24 |
2024-02-08 | LEIDEN JEFFREY M | Executive Chairman | D - F-InKind | Common Stock | 2698 | 421.73 |
2024-02-09 | LEIDEN JEFFREY M | Executive Chairman | D - F-InKind | Common Stock | 8048 | 422.74 |
2024-02-07 | WAGNER CHARLES F JR | EVP & Chief Financial Officer | A - A-Award | Common Stock | 7114 | 0 |
2024-02-06 | WAGNER CHARLES F JR | EVP & Chief Financial Officer | A - A-Award | Common Stock | 9440 | 0 |
2024-02-06 | WAGNER CHARLES F JR | EVP & Chief Financial Officer | A - A-Award | Common Stock | 5814 | 0 |
2024-02-07 | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | A - A-Award | Common Stock | 7114 | 0 |
2024-02-06 | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | A - A-Award | Common Stock | 7866 | 0 |
2024-02-06 | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | A - A-Award | Common Stock | 6976 | 0 |
2024-02-07 | Sachdev Amit | EVP Chief Patient & Ext Af Off | A - A-Award | Common Stock | 7114 | 0 |
2024-02-06 | Sachdev Amit | EVP Chief Patient & Ext Af Off | A - A-Award | Common Stock | 7866 | 0 |
2024-02-06 | Sachdev Amit | EVP Chief Patient & Ext Af Off | A - A-Award | Common Stock | 5814 | 0 |
2024-02-07 | LEIDEN JEFFREY M | Executive Chairman | A - A-Award | Common Stock | 7707 | 0 |
2024-02-06 | LEIDEN JEFFREY M | Executive Chairman | A - A-Award | Common Stock | 20452 | 0 |
2024-02-06 | LEIDEN JEFFREY M | Executive Chairman | A - A-Award | Common Stock | 10464 | 0 |
2024-02-07 | Kewalramani Reshma | CEO & President | A - A-Award | Common Stock | 20327 | 0 |
2024-02-06 | Kewalramani Reshma | CEO & President | A - A-Award | Common Stock | 26972 | 0 |
2024-02-06 | Kewalramani Reshma | CEO & President | A - A-Award | Common Stock | 14516 | 0 |
2024-02-07 | Bozic Carmen | EVP and CMO | A - A-Award | Common Stock | 5928 | 0 |
2024-02-06 | Bozic Carmen | EVP and CMO | A - A-Award | Common Stock | 7866 | 0 |
2024-02-06 | Bozic Carmen | EVP and CMO | A - A-Award | Common Stock | 5814 | 0 |
2024-02-07 | Biller Jonathan | EVP and Chief Legal Officer | A - A-Award | Common Stock | 4743 | 0 |
2024-02-06 | Biller Jonathan | EVP and Chief Legal Officer | A - A-Award | Common Stock | 6294 | 0 |
2024-02-07 | Atkinson Edward Morrow III | EVP, Chief Technical Ops. Off. | A - A-Award | Common Stock | 4743 | 0 |
2024-02-06 | Atkinson Edward Morrow III | EVP, Chief Technical Ops. Off. | A - A-Award | Common Stock | 3934 | 0 |
2024-02-06 | Atkinson Edward Morrow III | EVP, Chief Technical Ops. Off. | A - A-Award | Common Stock | 2326 | 0 |
2024-02-07 | Arbuckle Stuart A | EVP, COO | A - A-Award | Common Stock | 8448 | 0 |
2024-02-06 | Arbuckle Stuart A | EVP, COO | A - A-Award | Common Stock | 11210 | 0 |
2024-02-06 | Arbuckle Stuart A | EVP, COO | A - A-Award | Common Stock | 6976 | 0 |
2024-02-07 | Ambrose Kristen | SVP & Chief Accounting Officer | A - A-Award | Common Stock | 1853 | 0 |
2024-02-06 | Ambrose Kristen | SVP & Chief Accounting Officer | A - A-Award | Common Stock | 2950 | 0 |
2024-02-07 | ALTSHULER DAVID | EVP, Global Research and CSO | A - A-Award | Common Stock | 7114 | 0 |
2024-02-06 | ALTSHULER DAVID | EVP, Global Research and CSO | A - A-Award | Common Stock | 7866 | 0 |
2024-02-06 | ALTSHULER DAVID | EVP, Global Research and CSO | A - A-Award | Common Stock | 5814 | 0 |
2024-01-12 | SACHS BRUCE I | director | A - A-Award | Deferred Stock Units | 101.042 | 0 |
2024-01-12 | MCKENZIE DIANA | director | A - A-Award | Deferred Stock Units | 76.503 | 0 |
2024-01-08 | LEIDEN JEFFREY M | Executive Chairman | D - S-Sale | Common Stock | 6648 | 419.07 |
2024-01-02 | WAGNER CHARLES F JR | EVP & Chief Financial Officer | D - S-Sale | Common Stock | 3000 | 405 |
2023-12-15 | Kewalramani Reshma | CEO & President | A - M-Exempt | Common Stock | 14077 | 187.53 |
2023-12-15 | Kewalramani Reshma | CEO & President | A - M-Exempt | Common Stock | 3058 | 155.57 |
2023-12-15 | Kewalramani Reshma | CEO & President | D - S-Sale | Common Stock | 17135 | 407 |
2023-12-15 | Kewalramani Reshma | CEO & President | D - M-Exempt | Stock Option (Right to Buy) | 14077 | 187.53 |
2023-12-15 | Kewalramani Reshma | CEO & President | D - M-Exempt | Stock Option (Right to Buy) | 3058 | 155.57 |
2023-12-13 | LEIDEN JEFFREY M | Executive Chairman | D - S-Sale | Common Stock | 13254 | 399.41 |
2023-12-13 | LEIDEN JEFFREY M | Executive Chairman | D - S-Sale | Common Stock | 100 | 400.19 |
2023-12-13 | Kewalramani Reshma | CEO & President | D - S-Sale | Common Stock | 5098 | 397 |
2023-12-13 | Arbuckle Stuart A | EVP, COO | A - M-Exempt | Common Stock | 8603 | 187.53 |
2023-12-13 | Arbuckle Stuart A | EVP, COO | D - S-Sale | Common Stock | 8603 | 399 |
2023-12-13 | Arbuckle Stuart A | EVP, COO | D - M-Exempt | Stock Option (Right to Buy) | 8603 | 187.53 |
2023-12-05 | Thornberry Nancy | director | A - A-Award | Common Stock | 1136 | 0 |
2023-12-05 | Thornberry Nancy | - | 0 | 0 | ||
2023-11-20 | WAGNER CHARLES F JR | EVP & Chief Financial Officer | D - S-Sale | Common Stock | 3000 | 349.88 |
2023-11-15 | Sachdev Amit | EVP Chief Patient & Ext Af Off | D - S-Sale | Common Stock | 35 | 369.92 |
2023-11-15 | ALTSHULER DAVID | EVP, Global Research and CSO | D - S-Sale | Common Stock | 19 | 369.92 |
2023-11-14 | Bozic Carmen | EVP and CMO | D - S-Sale | Common Stock | 5650 | 380.82 |
2023-11-13 | Kewalramani Reshma | CEO & President | D - S-Sale | Common Stock | 5097 | 377 |
2023-11-06 | SACHS BRUCE I | director | A - M-Exempt | Common Stock | 11250 | 127.54 |
2023-11-06 | SACHS BRUCE I | director | D - S-Sale | Common Stock | 11250 | 385 |
2023-11-06 | SACHS BRUCE I | director | D - M-Exempt | Stock Option (Right to Buy) | 11250 | 127.54 |
2023-10-31 | Bozic Carmen | EVP and CMO | D - S-Sale | Common Stock | 5651 | 355.92 |
2023-10-17 | Bozic Carmen | EVP and CMO | D - S-Sale | Common Stock | 5651 | 373.25 |
2023-10-17 | Bhatia Sangeeta N. | director | D - S-Sale | Common Stock | 243 | 375 |
2023-10-16 | LEIDEN JEFFREY M | Executive Chairman | D - S-Sale | Common Stock | 12962 | 374 |
2023-10-13 | SACHS BRUCE I | director | A - A-Award | Deferred Stock Units | 118.25 | 0 |
2023-10-13 | MCKENZIE DIANA | director | A - A-Award | Deferred Stock Units | 89.532 | 0 |
2023-10-06 | Bhatia Sangeeta N. | director | D - S-Sale | Common Stock | 242 | 360 |
2023-10-05 | Lagarde Michel | director | A - A-Award | Common Stock | 1132 | 0 |
2023-10-05 | Lagarde Michel | - | 0 | 0 | ||
2023-10-03 | Bozic Carmen | EVP and CMO | D - S-Sale | Common Stock | 5651 | 345.28 |
2023-09-29 | Biller Jonathan | EVP and Chief Legal Officer | D - F-InKind | Common Stock | 408 | 350.72 |
2023-10-02 | Biller Jonathan | EVP and Chief Legal Officer | D - S-Sale | Common Stock | 610 | 346.76 |
2023-09-19 | Bozic Carmen | EVP and CMO | D - S-Sale | Common Stock | 5651 | 351 |
2023-09-05 | Bozic Carmen | EVP and CMO | D - S-Sale | Common Stock | 5651 | 352.66 |
2023-08-29 | Atkinson Edward Morrow III | EVP, Chief Technical Ops. Off. | D - | Common Stock | 0 | 0 |
2023-08-23 | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | D - S-Sale | Common Stock | 2500 | 355 |
2023-08-10 | Kearney Terrence C | director | A - M-Exempt | Common Stock | 10000 | 127.54 |
2023-08-10 | Kearney Terrence C | director | D - M-Exempt | Stock Option (Right to Buy) | 10000 | 127.54 |
2023-08-10 | Kearney Terrence C | director | D - S-Sale | Common Stock | 10000 | 350 |
2023-08-10 | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | D - S-Sale | Common Stock | 5750 | 345.79 |
2023-08-10 | Sachdev Amit | EVP, Chief Patient Officer | D - S-Sale | Common Stock | 10031 | 350 |
2023-08-09 | ALTSHULER DAVID | EVP, Global Research and CSO | D - S-Sale | Common Stock | 63 | 345.51 |
2023-08-09 | Bhatia Sangeeta N. | director | D - S-Sale | Common Stock | 242 | 345.51 |
2023-07-17 | SACHS BRUCE I | director | A - M-Exempt | Common Stock | 11250 | 127.54 |
2023-07-17 | SACHS BRUCE I | director | D - S-Sale | Common Stock | 1697 | 355.54 |
2023-07-17 | SACHS BRUCE I | director | D - S-Sale | Common Stock | 5711 | 356.75 |
2023-07-17 | SACHS BRUCE I | director | D - S-Sale | Common Stock | 3842 | 357.29 |
2023-07-14 | SACHS BRUCE I | director | A - A-Award | Deferred Stock Units | 124.719 | 0 |
2023-07-17 | SACHS BRUCE I | director | D - M-Exempt | Stock Option (Right to Buy) | 11250 | 127.54 |
2023-07-14 | MCKENZIE DIANA | director | A - A-Award | Deferred Stock Units | 89.927 | 0 |
2023-07-17 | Kewalramani Reshma | CEO & President | D - S-Sale | Common Stock | 7828 | 355 |
2023-06-15 | Arbuckle Stuart A | EVP, COO | A - M-Exempt | Common Stock | 8603 | 187.53 |
2023-06-15 | Arbuckle Stuart A | EVP, COO | D - S-Sale | Common Stock | 8603 | 349 |
2023-06-15 | Arbuckle Stuart A | EVP, COO | D - M-Exempt | Stock Option (Right to Buy) | 8603 | 187.53 |
2023-05-30 | Arbuckle Stuart A | EVP, COO | D - S-Sale | Common Stock | 82 | 329.82 |
2023-05-30 | Ambrose Kristen | SVP & Chief Accounting Officer | D - S-Sale | Common Stock | 289 | 329.82 |
2023-05-05 | Sanna Bastiano | EVP, Cell & Genetic Therapies | D - S-Sale | Common Stock | 422 | 350.03 |
2023-05-08 | Sanna Bastiano | EVP, Cell & Genetic Therapies | D - S-Sale | Common Stock | 2850 | 350 |
2023-05-05 | LEIDEN JEFFREY M | Executive Chairman | D - S-Sale | Common Stock | 708 | 349.38 |
2023-05-05 | LEIDEN JEFFREY M | Executive Chairman | D - S-Sale | Common Stock | 171 | 350.3 |
2023-05-08 | LEIDEN JEFFREY M | Executive Chairman | D - S-Sale | Common Stock | 1125 | 349 |
2023-05-02 | Sanna Bastiano | EVP, Cell & Genetic Therapies | D - S-Sale | Common Stock | 1411 | 350.32 |
2023-05-02 | Sanna Bastiano | EVP, Cell & Genetic Therapies | D - S-Sale | Common Stock | 42 | 351.65 |
2023-05-02 | Sanna Bastiano | EVP, Cell & Genetic Therapies | D - S-Sale | Common Stock | 169 | 353.24 |
2023-05-03 | Sanna Bastiano | EVP, Cell & Genetic Therapies | D - S-Sale | Common Stock | 2053 | 350.44 |
2023-05-03 | Sanna Bastiano | EVP, Cell & Genetic Therapies | D - S-Sale | Common Stock | 728 | 351.6 |
2023-05-02 | LEIDEN JEFFREY M | Executive Chairman | D - S-Sale | Common Stock | 4645 | 349.48 |
2023-05-02 | LEIDEN JEFFREY M | Executive Chairman | D - S-Sale | Common Stock | 1505 | 350.48 |
2023-05-02 | LEIDEN JEFFREY M | Executive Chairman | D - S-Sale | Common Stock | 300 | 353.18 |
2023-05-03 | LEIDEN JEFFREY M | Executive Chairman | D - S-Sale | Common Stock | 2008 | 349.22 |
2023-05-03 | LEIDEN JEFFREY M | Executive Chairman | D - S-Sale | Common Stock | 1800 | 350.53 |
2023-05-03 | LEIDEN JEFFREY M | Executive Chairman | D - S-Sale | Common Stock | 700 | 351.59 |
2023-05-01 | Upadhyay Suketu | director | A - A-Award | Common Stock | 1168 | 0 |
2023-05-01 | SACHS BRUCE I | director | A - A-Award | Stock Option (Right to Buy) | 3481 | 342.73 |
2023-05-01 | MCKENZIE DIANA | director | A - A-Award | Deferred Stock Units | 1449 | 0 |
2023-05-01 | MCKENZIE DIANA | director | A - A-Award | Common Stock | 1168 | 0 |
2023-05-01 | MCKENZIE DIANA | director | D - D-Return | Common Stock | 1449 | 0 |
2023-05-01 | MCGLYNN MARGARET G | director | A - A-Award | Stock Option (Right to Buy) | 3481 | 342.73 |
2023-05-01 | Lee Yuchun | director | A - A-Award | Stock Option (Right to Buy) | 3481 | 342.73 |
2023-05-01 | Kearney Terrence C | director | A - A-Award | Stock Option (Right to Buy) | 3481 | 342.73 |
2023-05-01 | Garber Alan M | director | A - A-Award | Common Stock | 584 | 0 |
2023-05-01 | Garber Alan M | director | A - A-Award | Stock Option (Right to Buy) | 1741 | 342.73 |
2023-05-01 | CARNEY LLOYD | director | A - A-Award | Common Stock | 1168 | 0 |
2023-05-01 | Bhatia Sangeeta N. | director | A - A-Award | Common Stock | 1168 | 0 |
2023-05-02 | Bhatia Sangeeta N. | director | D - S-Sale | Common Stock | 62 | 345.93 |
2023-05-02 | Bhatia Sangeeta N. | director | D - S-Sale | Common Stock | 172 | 346.69 |
2023-05-02 | Bhatia Sangeeta N. | director | D - S-Sale | Common Stock | 120 | 348.16 |
2023-05-02 | Bhatia Sangeeta N. | director | D - S-Sale | Common Stock | 163 | 349.82 |
2023-05-02 | Bhatia Sangeeta N. | director | D - S-Sale | Common Stock | 63 | 351.2 |
2023-04-27 | Kewalramani Reshma | CEO & President | D - S-Sale | Common Stock | 1611 | 338.69 |
2023-04-27 | Kewalramani Reshma | CEO & President | D - S-Sale | Common Stock | 1668 | 339.43 |
2023-04-27 | Kewalramani Reshma | CEO & President | D - S-Sale | Common Stock | 38 | 340.19 |
2023-04-14 | SACHS BRUCE I | director | A - A-Award | Deferred Stock Units | 131.473 | 0 |
2023-04-14 | MCKENZIE DIANA | director | A - A-Award | Deferred Stock Units | 90.153 | 0 |
2023-04-12 | Sanna Bastiano | EVP, Cell & Genetic Therapies | D - S-Sale | Common Stock | 874 | 325.7 |
2023-04-12 | Sanna Bastiano | EVP, Cell & Genetic Therapies | D - S-Sale | Common Stock | 4068 | 326.45 |
2023-04-12 | Sanna Bastiano | EVP, Cell & Genetic Therapies | D - S-Sale | Common Stock | 2625 | 327.43 |
2023-04-12 | SACHS BRUCE I | director | A - M-Exempt | Common Stock | 21300 | 72.14 |
2023-04-12 | SACHS BRUCE I | director | D - S-Sale | Common Stock | 2917 | 325.65 |
2023-04-12 | SACHS BRUCE I | director | D - S-Sale | Common Stock | 10357 | 326.46 |
2023-04-12 | SACHS BRUCE I | director | D - S-Sale | Common Stock | 8026 | 327.48 |
2023-04-13 | SACHS BRUCE I | director | D - G-Gift | Common Stock | 1210 | 0 |
2023-04-12 | SACHS BRUCE I | director | D - M-Exempt | Stock Option (Right to Buy) | 21300 | 72.14 |
2023-04-04 | Sanna Bastiano | EVP, Cell & Genetic Therapies | D - S-Sale | Common Stock | 211 | 314.22 |
2023-04-04 | Sanna Bastiano | EVP, Cell & Genetic Therapies | D - S-Sale | Common Stock | 94 | 315.66 |
2023-04-04 | Sanna Bastiano | EVP, Cell & Genetic Therapies | D - S-Sale | Common Stock | 90 | 316.76 |
2023-04-04 | Sanna Bastiano | EVP, Cell & Genetic Therapies | D - S-Sale | Common Stock | 96 | 317.65 |
2023-04-04 | Sanna Bastiano | EVP, Cell & Genetic Therapies | D - S-Sale | Common Stock | 31 | 318.68 |
2023-03-31 | Sanna Bastiano | EVP, Cell & Genetic Therapies | D - F-InKind | Common Stock | 1466 | 313.74 |
2023-03-24 | WAGNER CHARLES F JR | EVP & Chief Financial Officer | D - S-Sale | Common Stock | 1768 | 305.38 |
2023-03-17 | WAGNER CHARLES F JR | EVP & Chief Financial Officer | D - S-Sale | Common Stock | 360 | 294.52 |
2023-03-17 | WAGNER CHARLES F JR | EVP & Chief Financial Officer | D - S-Sale | Common Stock | 784 | 295.43 |
2023-03-17 | WAGNER CHARLES F JR | EVP & Chief Financial Officer | D - S-Sale | Common Stock | 240 | 296.3 |
2023-03-17 | WAGNER CHARLES F JR | EVP & Chief Financial Officer | D - S-Sale | Common Stock | 360 | 298.09 |
2023-03-17 | WAGNER CHARLES F JR | EVP & Chief Financial Officer | D - S-Sale | Common Stock | 240 | 299.58 |
2023-03-17 | WAGNER CHARLES F JR | EVP & Chief Financial Officer | D - S-Sale | Common Stock | 16 | 301.13 |
2023-03-16 | Sanna Bastiano | EVP, Cell & Genetic Therapies | D - S-Sale | Common Stock | 2482 | 300.54 |
2023-03-16 | Sanna Bastiano | EVP, Cell & Genetic Therapies | D - S-Sale | Common Stock | 264 | 301.07 |
2023-03-10 | WAGNER CHARLES F JR | EVP & Chief Financial Officer | D - S-Sale | Common Stock | 361 | 286.64 |
2023-03-10 | WAGNER CHARLES F JR | EVP & Chief Financial Officer | D - S-Sale | Common Stock | 515 | 287.83 |
2023-03-10 | WAGNER CHARLES F JR | EVP & Chief Financial Officer | D - S-Sale | Common Stock | 327 | 288.91 |
2023-03-10 | WAGNER CHARLES F JR | EVP & Chief Financial Officer | D - S-Sale | Common Stock | 30 | 289.44 |
2023-03-10 | WAGNER CHARLES F JR | EVP & Chief Financial Officer | D - S-Sale | Common Stock | 541 | 291.47 |
2023-03-10 | WAGNER CHARLES F JR | EVP & Chief Financial Officer | D - S-Sale | Common Stock | 185 | 292.68 |
2023-03-10 | WAGNER CHARLES F JR | EVP & Chief Financial Officer | D - S-Sale | Common Stock | 27 | 293.61 |
2023-03-10 | WAGNER CHARLES F JR | EVP & Chief Financial Officer | D - S-Sale | Common Stock | 102 | 294.94 |
2023-03-13 | WAGNER CHARLES F JR | EVP & Chief Financial Officer | D - S-Sale | Common Stock | 24 | 288.31 |
2023-03-13 | WAGNER CHARLES F JR | EVP & Chief Financial Officer | D - S-Sale | Common Stock | 420 | 292.41 |
2023-03-13 | WAGNER CHARLES F JR | EVP & Chief Financial Officer | D - S-Sale | Common Stock | 1153 | 293.35 |
2023-03-13 | WAGNER CHARLES F JR | EVP & Chief Financial Officer | D - S-Sale | Common Stock | 715 | 294.52 |
2023-03-13 | WAGNER CHARLES F JR | EVP & Chief Financial Officer | D - S-Sale | Common Stock | 292 | 295.89 |
2023-03-13 | WAGNER CHARLES F JR | EVP & Chief Financial Officer | D - S-Sale | Common Stock | 62 | 296.77 |
2023-02-24 | WAGNER CHARLES F JR | EVP & Chief Financial Officer | D - F-InKind | Common Stock | 3308 | 289.12 |
2023-02-24 | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | D - F-InKind | Common Stock | 3308 | 289.12 |
2023-02-27 | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | D - S-Sale | Common Stock | 283 | 287.2 |
2023-02-27 | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | D - S-Sale | Common Stock | 51 | 288.33 |
2023-02-27 | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | D - S-Sale | Common Stock | 20 | 289.29 |
2023-02-24 | Sanna Bastiano | EVP, Cell & Genetic Therapies | D - F-InKind | Common Stock | 3970 | 289.12 |
2023-02-24 | Sachdev Amit | EVP, Chief Patient Officer | D - F-InKind | Common Stock | 2468 | 289.12 |
2023-02-24 | LEIDEN JEFFREY M | Executive Chairman | D - F-InKind | Common Stock | 13730 | 289.12 |
2023-02-24 | Kewalramani Reshma | CEO & President | D - F-InKind | Common Stock | 9386 | 289.12 |
2023-02-24 | Bozic Carmen | EVP and CMO | D - F-InKind | Common Stock | 3308 | 289.12 |
2023-02-24 | Arbuckle Stuart A | EVP, COO | D - F-InKind | Common Stock | 4714 | 289.12 |
2023-02-27 | Arbuckle Stuart A | EVP, COO | D - S-Sale | Common Stock | 3834 | 287.16 |
2023-02-27 | Arbuckle Stuart A | EVP, COO | D - S-Sale | Common Stock | 400 | 287.59 |
2023-02-27 | Arbuckle Stuart A | EVP, COO | D - S-Sale | Common Stock | 800 | 288.92 |
2023-02-24 | Ambrose Kristen | SVP & Chief Accounting Officer | D - F-InKind | Common Stock | 502 | 289.12 |
2023-02-27 | Ambrose Kristen | SVP & Chief Accounting Officer | D - S-Sale | Common Stock | 982 | 287.25 |
2023-02-27 | Ambrose Kristen | SVP & Chief Accounting Officer | D - S-Sale | Common Stock | 183 | 288.68 |
2023-02-27 | Ambrose Kristen | SVP & Chief Accounting Officer | D - S-Sale | Common Stock | 42 | 289.63 |
2023-02-24 | ALTSHULER DAVID | EVP, Global Research and CSO | D - F-InKind | Common Stock | 3970 | 289.12 |
2023-02-27 | ALTSHULER DAVID | EVP, Global Research and CSO | D - S-Sale | Common Stock | 3636 | 287.23 |
2023-02-27 | ALTSHULER DAVID | EVP, Global Research and CSO | D - S-Sale | Common Stock | 300 | 288.74 |
2023-02-27 | ALTSHULER DAVID | EVP, Global Research and CSO | D - S-Sale | Common Stock | 302 | 289.6 |
2023-02-22 | Arbuckle Stuart A | EVP, COO | D - S-Sale | Common Stock | 129 | 291.84 |
2023-02-22 | Arbuckle Stuart A | EVP, COO | D - S-Sale | Common Stock | 300 | 292.86 |
2023-02-22 | Arbuckle Stuart A | EVP, COO | D - S-Sale | Common Stock | 1378 | 294.29 |
2023-02-22 | Arbuckle Stuart A | EVP, COO | D - S-Sale | Common Stock | 394 | 295.38 |
2023-02-22 | Arbuckle Stuart A | EVP, COO | D - S-Sale | Common Stock | 200 | 296.31 |
2023-02-17 | WAGNER CHARLES F JR | EVP & Chief Financial Officer | D - F-InKind | Common Stock | 3750 | 292.85 |
2023-02-17 | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | D - F-InKind | Common Stock | 4498 | 292.85 |
2023-02-21 | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | D - S-Sale | Common Stock | 4 | 291.01 |
2023-02-21 | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | D - S-Sale | Common Stock | 145 | 292.85 |
2023-02-21 | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | D - S-Sale | Common Stock | 207 | 293.83 |
2023-02-21 | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | D - S-Sale | Common Stock | 124 | 294.77 |
2023-02-17 | Sanna Bastiano | EVP, Cell & Genetic Therapies | D - F-InKind | Common Stock | 3750 | 292.85 |
2023-02-17 | Sachdev Amit | EVP, Chief Patient Officer | D - F-InKind | Common Stock | 3498 | 292.85 |
2023-02-17 | Kewalramani Reshma | CEO & President | D - F-InKind | Common Stock | 9359 | 292.85 |
2023-02-17 | Bozic Carmen | EVP and CMO | D - F-InKind | Common Stock | 3750 | 292.85 |
2023-02-17 | Arbuckle Stuart A | EVP, COO | D - F-InKind | Common Stock | 4498 | 292.85 |
2023-02-21 | Arbuckle Stuart A | EVP, COO | D - S-Sale | Common Stock | 21 | 291.01 |
2023-02-21 | Arbuckle Stuart A | EVP, COO | D - S-Sale | Common Stock | 545 | 292.77 |
2023-02-21 | Arbuckle Stuart A | EVP, COO | D - S-Sale | Common Stock | 1100 | 293.74 |
2023-02-21 | Arbuckle Stuart A | EVP, COO | D - S-Sale | Common Stock | 736 | 294.58 |
2023-02-17 | ALTSHULER DAVID | EVP, Global Research and CSO | D - F-InKind | Common Stock | 3750 | 292.85 |
2023-02-21 | ALTSHULER DAVID | EVP, Global Research and CSO | D - S-Sale | Common Stock | 36 | 291.01 |
2023-02-21 | ALTSHULER DAVID | EVP, Global Research and CSO | D - S-Sale | Common Stock | 1223 | 292.76 |
2023-02-21 | ALTSHULER DAVID | EVP, Global Research and CSO | D - S-Sale | Common Stock | 1843 | 294.03 |
2023-02-21 | ALTSHULER DAVID | EVP, Global Research and CSO | D - S-Sale | Common Stock | 900 | 294.73 |
2023-02-14 | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | D - S-Sale | Common Stock | 71 | 295.89 |
2023-02-14 | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | D - S-Sale | Common Stock | 20 | 296.48 |
2023-02-14 | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | D - S-Sale | Common Stock | 43 | 297.98 |
2023-02-14 | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | D - S-Sale | Common Stock | 135 | 299.6 |
2023-02-14 | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | D - S-Sale | Common Stock | 51 | 300.58 |
2023-02-14 | Sanna Bastiano | EVP, Cell & Genetic Therapies | D - S-Sale | Common Stock | 1902 | 300.29 |
2023-02-14 | Sanna Bastiano | EVP, Cell & Genetic Therapies | D - S-Sale | Common Stock | 279 | 301.11 |
2023-02-14 | Arbuckle Stuart A | EVP, COO | D - S-Sale | Common Stock | 800 | 295.84 |
2023-02-14 | Arbuckle Stuart A | EVP, COO | D - S-Sale | Common Stock | 901 | 296.85 |
2023-02-14 | Arbuckle Stuart A | EVP, COO | D - S-Sale | Common Stock | 560 | 298.14 |
2023-02-14 | Arbuckle Stuart A | EVP, COO | D - S-Sale | Common Stock | 2003 | 299.13 |
2023-02-14 | Arbuckle Stuart A | EVP, COO | D - S-Sale | Common Stock | 1734 | 300.09 |
2023-02-14 | Arbuckle Stuart A | EVP, COO | D - S-Sale | Common Stock | 400 | 300.89 |
2023-02-14 | ALTSHULER DAVID | EVP, Global Research and CSO | D - S-Sale | Common Stock | 800 | 295.79 |
2023-02-14 | ALTSHULER DAVID | EVP, Global Research and CSO | D - S-Sale | Common Stock | 842 | 296.85 |
2023-02-14 | ALTSHULER DAVID | EVP, Global Research and CSO | D - S-Sale | Common Stock | 395 | 297.97 |
2023-02-14 | ALTSHULER DAVID | EVP, Global Research and CSO | D - S-Sale | Common Stock | 2165 | 299.08 |
2023-02-14 | ALTSHULER DAVID | EVP, Global Research and CSO | D - S-Sale | Common Stock | 1888 | 300.11 |
2023-02-14 | ALTSHULER DAVID | EVP, Global Research and CSO | D - S-Sale | Common Stock | 308 | 301.02 |
2023-02-10 | WAGNER CHARLES F JR | EVP & Chief Financial Officer | D - F-InKind | Common Stock | 2707 | 294.33 |
2023-02-13 | WAGNER CHARLES F JR | EVP & Chief Financial Officer | D - F-InKind | Common Stock | 4992 | 298.26 |
2023-02-10 | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | D - F-InKind | Common Stock | 1377 | 294.33 |
2023-02-13 | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | D - F-InKind | Common Stock | 2995 | 298.26 |
2023-02-13 | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | D - S-Sale | Common Stock | 2 | 295.84 |
2023-02-13 | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | D - S-Sale | Common Stock | 78 | 298.11 |
2023-02-13 | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | D - S-Sale | Common Stock | 120 | 298.98 |
2023-02-13 | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | D - S-Sale | Common Stock | 64 | 299.88 |
2023-02-13 | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | D - S-Sale | Common Stock | 11 | 300.79 |
2023-02-10 | Sanna Bastiano | EVP, Cell & Genetic Therapies | D - F-InKind | Common Stock | 902 | 294.33 |
2023-02-13 | Sanna Bastiano | EVP, Cell & Genetic Therapies | D - F-InKind | Common Stock | 4340 | 298.26 |
2023-02-13 | Sanna Bastiano | EVP, Cell & Genetic Therapies | D - S-Sale | Common Stock | 113 | 300.39 |
2023-02-10 | Sachdev Amit | EVP, Chief Patient Officer | D - F-InKind | Common Stock | 2611 | 294.33 |
2023-02-13 | Sachdev Amit | EVP, Chief Patient Officer | D - F-InKind | Common Stock | 4657 | 298.26 |
2023-02-13 | LEIDEN JEFFREY M | Executive Chairman | D - F-InKind | Common Stock | 13344 | 298.26 |
2023-02-10 | Kewalramani Reshma | CEO & President | D - F-InKind | Common Stock | 3372 | 294.33 |
2023-02-13 | Kewalramani Reshma | CEO & President | D - F-InKind | Common Stock | 5990 | 298.26 |
2023-02-10 | Bozic Carmen | EVP and CMO | D - F-InKind | Common Stock | 2707 | 294.33 |
2023-02-13 | Bozic Carmen | EVP and CMO | D - F-InKind | Common Stock | 4992 | 298.26 |
2023-02-10 | Arbuckle Stuart A | EVP, COO | D - F-InKind | Common Stock | 3372 | 294.33 |
2023-02-13 | Arbuckle Stuart A | EVP, COO | D - F-InKind | Common Stock | 5990 | 298.26 |
2023-02-13 | Arbuckle Stuart A | EVP, COO | D - S-Sale | Common Stock | 245 | 296.44 |
2023-02-13 | Arbuckle Stuart A | EVP, COO | D - S-Sale | Common Stock | 2028 | 298.42 |
2023-02-13 | Arbuckle Stuart A | EVP, COO | D - S-Sale | Common Stock | 1779 | 299.26 |
2023-02-13 | Arbuckle Stuart A | EVP, COO | D - S-Sale | Common Stock | 835 | 300.13 |
2023-02-10 | ALTSHULER DAVID | EVP, Global Research and CSO | D - F-InKind | Common Stock | 3461 | 294.33 |
2023-02-13 | ALTSHULER DAVID | EVP, Global Research and CSO | D - F-InKind | Common Stock | 5990 | 298.26 |
2023-02-13 | ALTSHULER DAVID | EVP, Global Research and CSO | D - S-Sale | Common Stock | 245 | 296.44 |
2023-02-13 | ALTSHULER DAVID | EVP, Global Research and CSO | D - S-Sale | Common Stock | 2160 | 298.47 |
2023-02-13 | ALTSHULER DAVID | EVP, Global Research and CSO | D - S-Sale | Common Stock | 1893 | 299.36 |
2023-02-13 | ALTSHULER DAVID | EVP, Global Research and CSO | D - S-Sale | Common Stock | 500 | 300.23 |
2023-02-06 | ALTSHULER DAVID | EVP, Global Research and CSO | A - M-Exempt | Common Stock | 1304 | 187.53 |
2023-02-06 | ALTSHULER DAVID | EVP, Global Research and CSO | D - S-Sale | Common Stock | 12 | 300.39 |
2023-02-06 | ALTSHULER DAVID | EVP, Global Research and CSO | D - S-Sale | Common Stock | 70 | 302 |
2023-02-06 | ALTSHULER DAVID | EVP, Global Research and CSO | D - S-Sale | Common Stock | 100 | 303.64 |
2023-02-06 | ALTSHULER DAVID | EVP, Global Research and CSO | D - S-Sale | Common Stock | 349 | 305.08 |
2023-02-06 | ALTSHULER DAVID | EVP, Global Research and CSO | D - S-Sale | Common Stock | 620 | 306.7 |
2023-02-06 | ALTSHULER DAVID | EVP, Global Research and CSO | D - S-Sale | Common Stock | 153 | 309.06 |
2023-02-06 | ALTSHULER DAVID | EVP, Global Research and CSO | D - M-Exempt | Stock Option (Right to Buy) | 1304 | 187.53 |
2023-02-01 | WAGNER CHARLES F JR | EVP & Chief Financial Officer | A - A-Award | Common Stock | 9440 | 0 |
2023-02-01 | WAGNER CHARLES F JR | EVP & Chief Financial Officer | A - A-Award | Common Stock | 10262 | 0 |
2023-02-01 | WAGNER CHARLES F JR | EVP & Chief Financial Officer | A - A-Award | Common Stock | 10324 | 0 |
2023-02-01 | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | A - A-Award | Common Stock | 7866 | 0 |
2023-02-01 | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | A - A-Award | Common Stock | 10262 | 0 |
2023-02-01 | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | A - A-Award | Common Stock | 6194 | 0 |
2023-02-01 | Sanna Bastiano | EVP, Cell & Genetic Therapies | A - A-Award | Common Stock | 7866 | 0 |
2023-02-01 | Sanna Bastiano | EVP, Cell & Genetic Therapies | A - A-Award | Common Stock | 12314 | 0 |
2023-02-01 | Sanna Bastiano | EVP, Cell & Genetic Therapies | A - A-Award | Common Stock | 9092 | 0 |
2023-02-01 | Sachdev Amit | EVP, Chief Patient Officer | A - A-Award | Common Stock | 7866 | 0 |
2023-02-01 | Sachdev Amit | EVP, Chief Patient Officer | A - A-Award | Common Stock | 8210 | 0 |
2023-02-01 | Sachdev Amit | EVP, Chief Patient Officer | A - A-Award | Common Stock | 10324 | 0 |
2022-05-17 | Sachdev Amit | EVP, Chief Patient Officer | D - G-Gift | Common Stock | 1672 | 0 |
2023-02-01 | LEIDEN JEFFREY M | Executive Chairman | A - A-Award | Common Stock | 10226 | 0 |
2023-02-02 | LEIDEN JEFFREY M | Executive Chairman | D - F-InKind | Common Stock | 3578 | 317.83 |
2023-02-01 | LEIDEN JEFFREY M | Executive Chairman | A - A-Award | Common Stock | 34890 | 0 |
2023-02-01 | LEIDEN JEFFREY M | Executive Chairman | A - A-Award | Common Stock | 31462 | 0 |
2023-02-01 | Kewalramani Reshma | CEO & President | A - A-Award | Common Stock | 26972 | 0 |
2023-02-01 | Kewalramani Reshma | CEO & President | A - A-Award | Common Stock | 29118 | 0 |
2023-02-01 | Kewalramani Reshma | CEO & President | A - A-Award | Common Stock | 12388 | 0 |
2023-02-01 | Bozic Carmen | EVP and CMO | A - A-Award | Common Stock | 7866 | 0 |
2023-02-01 | Bozic Carmen | EVP and CMO | A - A-Award | Common Stock | 10262 | 0 |
2023-02-01 | Bozic Carmen | EVP and CMO | A - A-Award | Common Stock | 10324 | 0 |
2023-02-01 | Biller Jonathan | EVP and Chief Legal Officer | A - A-Award | Common Stock | 6293 | 0 |
2023-02-01 | Arbuckle Stuart A | EVP, COO | A - A-Award | Common Stock | 11209 | 0 |
2023-02-01 | Arbuckle Stuart A | EVP, COO | A - A-Award | Common Stock | 14624 | 0 |
2023-02-01 | Arbuckle Stuart A | EVP, COO | A - A-Award | Common Stock | 12388 | 0 |
2023-02-01 | Ambrose Kristen | SVP & Chief Accounting Officer | A - A-Award | Common Stock | 2950 | 0 |
2023-02-01 | Ambrose Kristen | SVP & Chief Accounting Officer | A - A-Award | Common Stock | 2566 | 0 |
2023-02-01 | ALTSHULER DAVID | EVP, Global Research and CSO | A - A-Award | Common Stock | 7866 | 0 |
2023-02-01 | ALTSHULER DAVID | EVP, Global Research and CSO | A - A-Award | Common Stock | 12314 | 0 |
2023-02-01 | ALTSHULER DAVID | EVP, Global Research and CSO | A - A-Award | Common Stock | 12388 | 0 |
2023-01-31 | Sanna Bastiano | EVP, Cell & Genetic Therapies | D - S-Sale | Common Stock | 106 | 325 |
2023-01-31 | SACHS BRUCE I | director | A - M-Exempt | Common Stock | 1200 | 72.14 |
2023-01-31 | SACHS BRUCE I | director | D - S-Sale | Common Stock | 1200 | 325.01 |
2023-01-31 | SACHS BRUCE I | director | D - M-Exempt | Stock Option (Right to Buy) | 1200 | 72.14 |
2023-01-30 | CARNEY LLOYD | director | D - S-Sale | Common Stock | 1376 | 320.08 |
2023-01-30 | CARNEY LLOYD | director | D - S-Sale | Common Stock | 1000 | 320.7 |
2023-01-30 | CARNEY LLOYD | director | D - S-Sale | Common Stock | 324 | 321.84 |
2023-01-27 | Lee Yuchun | director | A - M-Exempt | Common Stock | 1429 | 72.14 |
2023-01-27 | Lee Yuchun | director | D - S-Sale | Common Stock | 379 | 321.31 |
2023-01-27 | Lee Yuchun | director | D - S-Sale | Common Stock | 970 | 322.2 |
2023-01-27 | Lee Yuchun | director | D - S-Sale | Common Stock | 80 | 323.33 |
2023-01-27 | Lee Yuchun | director | D - M-Exempt | Stock Option (Right to Buy) | 1429 | 72.14 |
2023-01-26 | Lee Yuchun | director | A - M-Exempt | Common Stock | 4000 | 72.14 |
2023-01-26 | Lee Yuchun | director | D - S-Sale | Common Stock | 302 | 315.42 |
2023-01-25 | Lee Yuchun | director | D - M-Exempt | Stock Option (Right to Buy) | 4000 | 0 |
2023-01-25 | Lee Yuchun | director | D - S-Sale | Common Stock | 800 | 312.8 |
2023-01-26 | Lee Yuchun | director | D - S-Sale | Common Stock | 1140 | 316.82 |
2023-01-26 | Lee Yuchun | director | D - S-Sale | Common Stock | 1000 | 317.95 |
2023-01-26 | Lee Yuchun | director | D - S-Sale | Common Stock | 478 | 319.25 |
2023-01-26 | Lee Yuchun | director | D - S-Sale | Common Stock | 400 | 320.25 |
2023-01-25 | Lee Yuchun | director | D - S-Sale | Common Stock | 2621 | 314.1 |
2023-01-26 | Lee Yuchun | director | D - S-Sale | Common Stock | 680 | 320.94 |
2023-01-26 | Lee Yuchun | director | D - M-Exempt | Stock Option (Right to Buy) | 4000 | 0 |
2023-01-25 | Kewalramani Reshma | CEO & President | D - S-Sale | Common Stock | 10000 | 315.05 |
2023-01-23 | Lee Yuchun | director | D - M-Exempt | Stock Option (Right to Buy) | 2129 | 0 |
2023-01-24 | Lee Yuchun | director | D - M-Exempt | Stock Option (Right to Buy) | 4000 | 0 |
2023-01-24 | Lee Yuchun | director | A - M-Exempt | Common Stock | 4000 | 72.14 |
2023-01-23 | Lee Yuchun | director | A - M-Exempt | Common Stock | 2129 | 72.14 |
2023-01-24 | Lee Yuchun | director | D - S-Sale | Common Stock | 2511 | 312.29 |
2023-01-24 | Lee Yuchun | director | D - S-Sale | Common Stock | 1489 | 313.36 |
2023-01-17 | Lee Yuchun | director | D - M-Exempt | Stock Option (Right to Buy) | 4000 | 0 |
2023-01-18 | Lee Yuchun | director | D - M-Exempt | Stock Option (Right to Buy) | 442 | 0 |
2023-01-17 | Lee Yuchun | director | A - M-Exempt | Common Stock | 4000 | 72.14 |
2023-01-18 | Lee Yuchun | director | A - M-Exempt | Common Stock | 442 | 72.14 |
2023-01-18 | Lee Yuchun | director | D - S-Sale | Common Stock | 442 | 312.17 |
2023-01-13 | Upadhyay Suketu | director | A - A-Award | Deferred Stock Units | 96.341 | 298.42 |
2023-01-13 | SACHS BRUCE I | director | A - A-Award | Deferred Stock Units | 146.606 | 298.42 |
2023-01-13 | MCKENZIE DIANA | director | A - A-Award | Deferred Stock Units | 100.53 | 298.42 |
2022-12-06 | Arbuckle Stuart A | EVP, COO | A - A-Award | Common Stock | 12753 | 0 |
2022-11-15 | ALTSHULER DAVID | EVP, Global Research and CSO | D - S-Sale | Common Stock | 34 | 308.61 |
2022-11-07 | ALTSHULER DAVID | EVP, Global Research and CSO | A - M-Exempt | Common Stock | 1303 | 187.53 |
2022-11-07 | ALTSHULER DAVID | EVP, Global Research and CSO | D - S-Sale | Common Stock | 140 | 299.72 |
2022-11-07 | ALTSHULER DAVID | EVP, Global Research and CSO | D - S-Sale | Common Stock | 210 | 300.96 |
2022-11-07 | ALTSHULER DAVID | EVP, Global Research and CSO | D - S-Sale | Common Stock | 189 | 301.99 |
2022-11-07 | ALTSHULER DAVID | EVP, Global Research and CSO | D - S-Sale | Common Stock | 261 | 303.21 |
2022-11-07 | ALTSHULER DAVID | EVP, Global Research and CSO | D - S-Sale | Common Stock | 280 | 304.58 |
2022-11-07 | ALTSHULER DAVID | EVP, Global Research and CSO | D - S-Sale | Common Stock | 140 | 305.39 |
2022-11-07 | ALTSHULER DAVID | EVP, Global Research and CSO | D - S-Sale | Common Stock | 83 | 306.57 |
2022-11-07 | ALTSHULER DAVID | EVP, Global Research and CSO | D - M-Exempt | Stock Option (Right to Buy) | 1303 | 0 |
2022-11-01 | Sanna Bastiano | EVP, Cell & Genetic Therapies | D - F-InKind | Common Stock | 768 | 312.84 |
2022-11-02 | Sanna Bastiano | EVP, Cell & Genetic Therapies | D - S-Sale | Common Stock | 56 | 310.1 |
2022-11-02 | Sanna Bastiano | EVP, Cell & Genetic Therapies | D - S-Sale | Common Stock | 39 | 311.17 |
2022-11-02 | Sanna Bastiano | EVP, Cell & Genetic Therapies | D - S-Sale | Common Stock | 100 | 312.4 |
2022-11-02 | Sanna Bastiano | EVP, Cell & Genetic Therapies | D - S-Sale | Common Stock | 81 | 313.37 |
2022-11-02 | Sanna Bastiano | EVP, Cell & Genetic Therapies | D - S-Sale | Common Stock | 12 | 314.43 |
2022-11-02 | Sanna Bastiano | EVP, Cell & Genetic Therapies | D - S-Sale | Common Stock | 10 | 315.68 |
2022-11-02 | Sanna Bastiano | EVP, Cell & Genetic Therapies | D - S-Sale | Common Stock | 22 | 317.77 |
2022-10-24 | Bhatia Sangeeta N. | director | D - S-Sale | Common Stock | 621 | 310 |
2022-10-18 | Sanna Bastiano | EVP, Cell & Genetic Therapies | D - S-Sale | Common Stock | 1503 | 300.02 |
2022-10-18 | Sanna Bastiano | EVP, Cell & Genetic Therapies | D - S-Sale | Common Stock | 288 | 301.84 |
2022-10-14 | Upadhyay Suketu | director | A - A-Award | Deferred Stock Units | 96.861 | 296.82 |
2022-10-14 | SACHS BRUCE I | director | A - A-Award | Deferred Stock Units | 147.396 | 296.82 |
2022-10-14 | MCKENZIE DIANA | director | A - A-Award | Deferred Stock Units | 101.072 | 296.82 |
2022-09-19 | Biller Jonathan | EVP and Chief Legal Officer | A - A-Award | Common Stock | 5294 | 0 |
2022-08-15 | Kewalramani Reshma | CEO & President | D - S-Sale | Common Stock | 11689 | 305.06 |
2022-08-15 | Arbuckle Stuart A | EVP, COO | A - M-Exempt | Common Stock | 6571 | 155.57 |
2022-08-15 | Arbuckle Stuart A | EVP, COO | D - S-Sale | Common Stock | 1254 | 300.3 |
2022-08-15 | Arbuckle Stuart A | EVP, COO | D - S-Sale | Common Stock | 4242 | 301.61 |
2022-08-15 | Arbuckle Stuart A | EVP, COO | D - S-Sale | Common Stock | 400 | 302.55 |
2022-08-15 | Arbuckle Stuart A | EVP, COO | D - S-Sale | Common Stock | 2339 | 303.78 |
2022-08-15 | Arbuckle Stuart A | EVP, COO | D - S-Sale | Common Stock | 6990 | 304.67 |
2022-08-15 | Arbuckle Stuart A | EVP, COO | D - S-Sale | Common Stock | 6948 | 305.38 |
2022-08-15 | Arbuckle Stuart A | EVP, COO | D - M-Exempt | Stock Option (Right to Buy) | 6571 | 155.57 |
2022-08-15 | Arbuckle Stuart A | EVP, COO | D - M-Exempt | Stock Option (Right to Buy) | 6571 | 0 |
2022-08-15 | Liu Joy | SVP, General Counsel | D - S-Sale | Common Stock | 698 | 301.63 |
2022-08-10 | Arbuckle Stuart A | EVP, COO | A - M-Exempt | Common Stock | 64 | 155.57 |
2022-08-10 | Arbuckle Stuart A | EVP, COO | D - S-Sale | Common Stock | 171 | 300.32 |
2022-08-10 | Arbuckle Stuart A | EVP, COO | D - S-Sale | Common Stock | 9 | 302.01 |
2022-08-10 | Arbuckle Stuart A | EVP, COO | D - M-Exempt | Stock Option (Right to Buy) | 64 | 0 |
2022-08-10 | Arbuckle Stuart A | EVP, COO | D - M-Exempt | Stock Option (Right to Buy) | 64 | 155.57 |
2022-08-10 | Liu Joy | SVP, General Counsel | D - S-Sale | Common Stock | 36 | 300.32 |
2022-08-08 | Bhatia Sangeeta N. | director | D - S-Sale | Common Stock | 45 | 290.18 |
2022-08-08 | Bhatia Sangeeta N. | director | D - S-Sale | Common Stock | 164 | 291.76 |
2022-08-08 | Bhatia Sangeeta N. | director | D - S-Sale | Common Stock | 204 | 293.15 |
2022-08-08 | Bhatia Sangeeta N. | director | D - S-Sale | Common Stock | 161 | 294.24 |
2022-08-08 | Bhatia Sangeeta N. | D - S-Sale | Common Stock | 47 | 295.53 | |
2022-08-09 | Liu Joy | SVP, General Counsel | D - S-Sale | Common Stock | 946 | 300 |
2022-08-09 | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | D - S-Sale | Common Stock | 292 | 297.54 |
2022-08-09 | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | D - S-Sale | Common Stock | 679 | 298.77 |
2022-08-09 | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | D - S-Sale | Common Stock | 283 | 299.79 |
2022-08-09 | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | D - S-Sale | Common Stock | 72 | 300.64 |
2022-08-09 | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | D - S-Sale | Common Stock | 74 | 301.67 |
2022-08-09 | Arbuckle Stuart A | EVP, COO | A - M-Exempt | Common Stock | 1926 | 155.57 |
2022-08-09 | Arbuckle Stuart A | EVP, COO | D - S-Sale | Common Stock | 4790 | 300.53 |
2022-08-09 | Arbuckle Stuart A | EVP, COO | D - S-Sale | Common Stock | 900 | 301.42 |
2022-08-09 | Arbuckle Stuart A | EVP, COO | D - M-Exempt | Stock Option (Right to Buy) | 1926 | 0 |
2022-08-09 | Arbuckle Stuart A | EVP, COO | D - M-Exempt | Stock Option (Right to Buy) | 1926 | 155.57 |
2022-08-08 | ALTSHULER DAVID | EVP, Global Research and CSO | D - S-Sale | Common Stock | 210 | 293.02 |
2022-08-08 | ALTSHULER DAVID | EVP, Global Research and CSO | D - M-Exempt | Stock Option (Right to Buy) | 1304 | 0 |
2022-08-01 | Sanna Bastiano | EVP, Cell & Genetic Therapies | D - F-InKind | Common Stock | 766 | 276.62 |
2022-07-29 | Bhatia Sangeeta N. | director | D - S-Sale | Common Stock | 99 | 276.65 |
2022-07-29 | Bhatia Sangeeta N. | director | D - S-Sale | Common Stock | 200 | 277.95 |
2022-07-29 | Bhatia Sangeeta N. | director | D - S-Sale | Common Stock | 160 | 279.28 |
2022-07-29 | Bhatia Sangeeta N. | director | D - S-Sale | Common Stock | 99 | 280.22 |
2022-07-29 | Bhatia Sangeeta N. | director | D - S-Sale | Common Stock | 58 | 281.03 |
2022-07-29 | Bhatia Sangeeta N. | D - S-Sale | Common Stock | 5 | 282.34 | |
2022-07-25 | LEIDEN JEFFREY M | Executive Chairman | D - M-Exempt | Stock Option (Right to Buy) | 60342 | 0 |
2022-07-25 | LEIDEN JEFFREY M | Executive Chairman | D - S-Sale | Common Stock | 40666 | 282.43 |
2022-07-19 | ALTSHULER DAVID | EVP, Global Research and CSO | D - S-Sale | Common Stock | 4561 | 287.83 |
2022-07-19 | ALTSHULER DAVID | EVP, Global Research and CSO | D - M-Exempt | Stock Option (Right to Buy) | 10427 | 0 |
2022-06-24 | Kewalramani Reshma | CEO & President | - | 0 | 0 | |
2022-07-15 | SACHS BRUCE I | A - A-Award | Deferred Stock Units | 151.264 | 289.23 | |
2022-07-15 | SACHS BRUCE I | director | A - A-Award | Deferred Stock Units | 151.264 | 0 |
2022-07-15 | MCKENZIE DIANA | director | A - A-Award | Deferred Stock Units | 95.081 | 0 |
2022-07-15 | MCKENZIE DIANA | A - A-Award | Deferred Stock Units | 95.081 | 289.23 | |
2022-07-15 | Upadhyay Suketu | A - A-Award | Deferred Stock Units | 41.794 | 289.23 | |
2022-07-15 | Upadhyay Suketu | director | A - A-Award | Deferred Stock Units | 41.794 | 0 |
2022-06-24 | Kewalramani Reshma | CEO & President | D - S-Sale | Common Stock | 11689 | 291.3 |
2022-05-31 | Bozic Carmen | EVP and CMO | D - F-InKind | Common Stock | 311 | 271.24 |
2022-05-18 | Upadhyay Suketu | A - A-Award | Common Stock | 1558 | 0 | |
2022-05-16 | Sanna Bastiano | EVP, Cell & Genetic Therapies | D - S-Sale | Common Stock | 8 | 254.44 |
2022-05-16 | Arbuckle Stuart A | EVP, COO | D - S-Sale | Common Stock | 11 | 246.21 |
2022-05-16 | Arbuckle Stuart A | EVP, COO | D - S-Sale | Common Stock | 10 | 247.95 |
2022-05-16 | Arbuckle Stuart A | EVP, COO | D - S-Sale | Common Stock | 20 | 249.35 |
2022-05-16 | Arbuckle Stuart A | EVP, COO | D - S-Sale | Common Stock | 32 | 250.78 |
2022-05-16 | Arbuckle Stuart A | EVP, COO | D - S-Sale | Common Stock | 10 | 251.43 |
2022-05-16 | Arbuckle Stuart A | EVP, COO | D - S-Sale | Common Stock | 10 | 252.66 |
2022-05-16 | Arbuckle Stuart A | EVP, COO | D - S-Sale | Common Stock | 40 | 254.19 |
2022-05-16 | Liu Joy | SVP, General Counsel | D - S-Sale | Common Stock | 35 | 254.36 |
2022-05-18 | Upadhyay Suketu | - | 0 | 0 | ||
2022-05-04 | Sanna Bastiano | EVP, Cell & Genetic Therapies | D - S-Sale | Common Stock | 36 | 275.09 |
2022-05-02 | Arbuckle Stuart A | EVP, COO | D - S-Sale | Common Stock | 306 | 263.98 |
2022-05-02 | Sanna Bastiano | EVP, Cell & Genetic Therapies | D - S-Sale | Common Stock | 4 | 264.37 |
2022-05-02 | Bhatia Sangeeta N. | D - S-Sale | Common Stock | 40 | 255.4 | |
2022-05-02 | Bhatia Sangeeta N. | director | D - S-Sale | Common Stock | 280 | 257.51 |
2022-05-02 | Bhatia Sangeeta N. | director | D - S-Sale | Common Stock | 120 | 258.9 |
2022-05-02 | Bhatia Sangeeta N. | director | D - S-Sale | Common Stock | 120 | 259.75 |
2022-05-02 | Bhatia Sangeeta N. | director | D - S-Sale | Common Stock | 80 | 260.82 |
2022-05-02 | Bhatia Sangeeta N. | director | D - S-Sale | Common Stock | 91 | 261.91 |
2022-05-02 | Bhatia Sangeeta N. | director | D - S-Sale | Common Stock | 6 | 264.37 |
2022-05-02 | WAGNER CHARLES F JR | EVP & Chief Financial Officer | D - S-Sale | Common Stock | 80 | 259.45 |
2022-05-01 | Kearney Terrence C | director | A - A-Award | Common Stock | 725 | 0 |
2022-05-01 | Kearney Terrence C | A - A-Award | Stock Option (Right to Buy) | 2231 | 0 | |
2022-05-01 | Kearney Terrence C | director | A - A-Award | Stock Option (Right to Buy) | 2231 | 276.17 |
2022-05-01 | Lee Yuchun | A - A-Award | Stock Option (Right to Buy) | 4462 | 0 | |
2022-05-01 | Lee Yuchun | director | A - A-Award | Stock Option (Right to Buy) | 4462 | 276.17 |
2022-05-01 | MCKENZIE DIANA | director | A - A-Award | Common Stock | 1449 | 0 |
2022-05-01 | MCKENZIE DIANA | A - A-Award | Deferred Stock Units | 1842 | 0 | |
2022-05-01 | MCKENZIE DIANA | D - D-Return | Common Stock | 1842 | 0 | |
2022-05-01 | Bhatia Sangeeta N. | A - A-Award | Common Stock | 1449 | 0 | |
2022-05-01 | MCGLYNN MARGARET G | A - A-Award | Deferred Stock Units | 921 | 0 | |
2022-05-01 | MCGLYNN MARGARET G | D - D-Return | Common Stock | 921 | 0 | |
2022-05-01 | CARNEY LLOYD | A - A-Award | Common Stock | 1449 | 0 | |
2022-05-01 | SACHS BRUCE I | A - A-Award | Stock Option (Right to Buy) | 4462 | 0 | |
2022-05-01 | SACHS BRUCE I | director | A - A-Award | Stock Option (Right to Buy) | 4462 | 276.17 |
2022-05-01 | Garber Alan M | A - A-Award | Stock Option (Right to Buy) | 4462 | 0 | |
2022-04-29 | Liu Joy | SVP, General Counsel | D - S-Sale | Common Stock | 22 | 276.72 |
2022-04-29 | WAGNER CHARLES F JR | EVP & Chief Financial Officer | D - F-InKind | Common Stock | 547 | 276.17 |
2022-04-29 | Sanna Bastiano | EVP, Cell & Genetic Therapies | D - F-InKind | Common Stock | 766 | 276.17 |
2022-04-25 | Ambrose Kristen | SVP & Chief Accounting Officer | D - S-Sale | Common Stock | 83 | 269.51 |
2022-04-18 | Lee Yuchun | A - M-Exempt | Common Stock | 2000 | 81.54 | |
2022-04-18 | Lee Yuchun | D - S-Sale | Common Stock | 382 | 282.7 | |
2022-04-18 | Lee Yuchun | director | D - S-Sale | Common Stock | 1008 | 284.06 |
2022-04-18 | Lee Yuchun | director | D - S-Sale | Common Stock | 491 | 285.16 |
2022-04-18 | Lee Yuchun | director | D - S-Sale | Common Stock | 119 | 286.8 |
2022-04-18 | Lee Yuchun | director | D - M-Exempt | Stock Option (Right to Buy) | 2000 | 81.54 |
2022-04-14 | Lee Yuchun | director | A - M-Exempt | Common Stock | 2000 | 81.54 |
2022-04-14 | Lee Yuchun | director | D - S-Sale | Common Stock | 948 | 287.87 |
2022-04-14 | Lee Yuchun | director | D - S-Sale | Common Stock | 252 | 288.92 |
2022-04-14 | Lee Yuchun | director | D - S-Sale | Common Stock | 400 | 289.84 |
2022-04-14 | Lee Yuchun | D - M-Exempt | Stock Option (Right to Buy) | 2000 | 0 | |
2022-04-14 | Lee Yuchun | director | D - M-Exempt | Stock Option (Right to Buy) | 2000 | 81.54 |
2022-04-14 | Lee Yuchun | D - S-Sale | Common Stock | 400 | 291.18 | |
2022-04-14 | MCKENZIE DIANA | A - A-Award | Deferred Stock Units | 95.021 | 289.41 | |
2022-04-14 | MCKENZIE DIANA | director | A - A-Award | Deferred Stock Units | 95.021 | 0 |
2022-04-14 | SACHS BRUCE I | A - A-Award | Deferred Stock Units | 151.17 | 289.41 | |
2022-04-14 | SACHS BRUCE I | director | A - A-Award | Deferred Stock Units | 151.17 | 0 |
2022-04-13 | LEIDEN JEFFREY M | Executive Chairman | D - S-Sale | Common Stock | 15789 | 289.04 |